@incollection{SchildmannBoettcherGabrieletal.2015, author = {Schildmann, Jan and B{\"o}ttcher, Miriam and Gabriel, Maria and Ganser, Arnold and Hessel, Franz and Gottwald, Sina}, title = {"Personalised medicine": Multidisciplinary perspectives and interdisciplinary recommendations on a framework for future research and practice}, series = {The Ethics of Personalised Medicine}, booktitle = {The Ethics of Personalised Medicine}, publisher = {Ashgate}, address = {Farnham}, publisher = {SRH Berlin University of Applied Sciences}, pages = {keine Angabe -- keine Angabe}, year = {2015}, abstract = {'Personalised medicine' (PM) has raised great hopes and expectations among researchers, patients, health-care providers and politicians in past years. Although the term 'person' in PM suggests an approach of medicine which takes into account psychosocial and value aspects of the patient as human being, most articles refer to PM as strategies limited to biological features of individuals which are used to stratify patient groups for the purposes of prevention, diagnosis and treatment of disease.}, language = {en} } @incollection{Hessel2015, author = {Hessel, Franz}, title = {HTA in Personalized Medicine Technologies}, series = {Biomarker Validation}, booktitle = {Biomarker Validation}, publisher = {Wiley-VCH}, address = {Weinheim}, publisher = {SRH Berlin University of Applied Sciences}, pages = {95 -- 106}, year = {2015}, abstract = {Beyond the proof of efficacy and safety for approval purposes health technology assessment (HTA) is a more comprehensive evaluation of all relevant short- and long-term consequences of the application of a specific medical technology. HTA is performed for the purpose of reimbursement decision making. It covers clinical, societal, economic, ethical and legal aspects based on the available scientific evidence. Although there are some special issues to be considered all principles of HTA are equally valid for the evaluation of biomarker tests and personalized medicine technologies. All requirements of evidence-based medicine remain and causality should and could only be demonstrated with high-quality controlled studies, preferably with randomized design. The multimodality of the intervention and by tendency smaller sample sizes lead to an increased amount of uncertainty. Besides the test strategy, itself also questions of test or sample quality, laboratory size, or the platform used, and the specific technology must be taken into consideration. Economic evaluations should also include these aspects. In summary the fundamental principles of HTA and health economic evaluation are also valid and feasible for the evaluation of personalized medicine and genetic biomarker tests, but careful adaptations of the existing HTA and health economic guidelines are required.}, language = {en} } @article{Hessel, author = {Hessel, Franz}, title = {Budget impact of computer-based psychotherapy in Germany}, series = {Value in Health}, journal = {Value in Health}, abstract = {Keine Angabe No details}, language = {en} } @incollection{BritzeBueschHesseletal.2016, author = {Britze, Nils and B{\"u}sch, Victoria and Hessel, Franz and St{\"a}hler, Tobias and Tern{\`e}s, Anabel}, title = {Die steigende Bedeutung des betrieblichen Demografie- und Gesundheitsmanagements im 21. Jahrhundert}, series = {Herausforderung Management}, volume = {2016}, booktitle = {Herausforderung Management}, publisher = {SRH Hochschule Heidelberg}, address = {Heidelberg}, publisher = {SRH Berlin University of Applied Sciences}, pages = {62 -- 79}, year = {2016}, abstract = {Keine Angabe No details}, language = {de} } @incollection{BueschHesselStaehleretal.2016, author = {B{\"u}sch, Victoria and Hessel, Franz and St{\"a}hler, Tobias and Tern{\`e}s, Anabel}, title = {Arbeitsf{\"a}higkeit von Mitarbeitern st{\"a}rken - Good-Practice-Beispiele}, series = {Trends im Betrieblichen Gesundheitsmanagement}, volume = {2016}, booktitle = {Trends im Betrieblichen Gesundheitsmanagement}, publisher = {Springer}, address = {Berlin}, publisher = {SRH Berlin University of Applied Sciences}, pages = {225 -- 236}, year = {2016}, abstract = {Obwohl die Diskussion zur Arbeitsf{\"a}higkeit der Belegschaft bereits durch Trends wie den demografischen Wandel angeregt wurde, sind entsprechende unternehmerische oder politische Umsetzungen noch selten. Um ein ganzheitliches Betriebliches Gesundheitsmanagement umzusetzen, fehlt es h{\"a}ufig an praxistauglichen Modellen und Anregungen. Dieses Kapitel stellt zun{\"a}chst Ilmarinens Work-Ability-Modell bzw. das empirische Werkzeug des Work-Ability-Index als m{\"o}gliche Ansatzpunkte f{\"u}r ein Betriebliches Gesundheitsmanagement vor und zeigt weiterhin Praxisbeispiele auf, die sich mit den Dimensionen bzw. Zielbereichen des Modells assoziieren lassen.}, language = {de} } @misc{Hessel2012, author = {Hessel, Franz}, title = {Verg{\"u}tung personalisierter Medizin}, year = {2012}, abstract = {Keine Angabe No details}, language = {de} } @misc{Hessel2012, author = {Hessel, Franz}, title = {Gesundheits{\"o}konomische Betrachtung kongenitaler Cytomegalie-Virus Infektionen}, year = {2012}, abstract = {Keine Angabe No details}, language = {de} } @misc{Hessel2012, author = {Hessel, Franz}, title = {Gesundheits{\"o}konomische Evaluation nicht nur f{\"u}r Arzneimittel: Diagnostika und Medizinprodukte}, year = {2012}, abstract = {Keine Angaben No details}, language = {de} } @misc{Hessel2012, author = {Hessel, Franz}, title = {Gesundheits{\"o}konomische Studien auf der Basis von Registerdaten}, year = {2012}, abstract = {Keine Angaben No details}, language = {de} } @misc{Hessel2012, author = {Hessel, Franz}, title = {Qualit{\"a}t der Versorgung von Substitutionspatienten anhand der Premos-Studie}, year = {2012}, abstract = {Keine Angabe No details}, language = {de} } @misc{Hessel2012, author = {Hessel, Franz}, title = {Auswirkungen des demografischen Wandels auf die Arbeitssituation von {\"A}rzten und Pflegekr{\"a}ften}, year = {2012}, abstract = {Keine Angabe No details}, language = {de} } @misc{Hessel2012, author = {Hessel, Franz}, title = {Aktuelle Aspekte der Pharma-{\"O}konomie}, year = {2012}, abstract = {Keine Angabe No details}, language = {de} }